“Hard to Reach” Is a Sponsor Operations Failure, Not a Population Problem
The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure...
Benchmark Scores Don’t Save Patients: Why Clinical AI Needs RCT-Grade Evidence Before It Touches a Workflow
Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets...
Mednet AI Intake Tool Automates EHR-to-EDC Data Entry in Clinical Trials
Mednet AI intake tool automates EHR-to-EDC data entry in clinical trials, reducing manual transcription and entry errors for research...
Hinge Bio Uses Single Medrio Platform for Phase I Trial Operations
Hinge Bio runs its Phase I trial on a single Medrio platform, consolidating EDC, ePRO, and RTSM to reduce...
Pulse Biosciences Closes PRECISE-BTN Thyroid Nodule Trial Enrollment
Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout...
FDA Aligns on Rocket Pharmaceuticals RP-A501 Phase 2 Trial Design for Danon Disease
FDA aligns on RP-A501 Phase 2 trial design for Danon disease, approving a 12-patient pivotal population and 12-month endpoint...
CRB-913 Obesity Drug Shows 5% Weight Loss in Phase 1b Trial
CRB-913 obesity drug achieved 5% weight loss in Phase 1b trial, signaling potential for a peripheral CB1 mechanism without...
TRUTAKNA Meets All Endpoints in Phase 3 IgA Nephropathy Trial Final Analysis
TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease progression prevention...
When the Scan Knows Before the Spirometer Does
Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT is...
FDA Hears 80 Speakers on Psychedelic Drug Therapy Standards
The FDA held a public hearing on psychedelic drug therapy, drawing more than 1,800 registered attendees and 80 speakers...